BACKGROUND: Prior research has shown that the Sadness Program, a technician-assisted Internet-based cognitive behavioral therapy (iCBT) intervention developed in Australia, is effective for treating major depressive disorder (MDD). The current study aimed to expand this work by adapting the protocol for an American population and testing the Sadness Program with an attention control group. METHODS: In this parallel-group, randomized controlled trial, adult MDD participants (18-45 years) were randomized to a 10-week period of iCBT (n = 37) or monitored attention control (MAC; n = 40). Participants in the iCBT group completed six online therapy lessons, which included access to content summaries and homework assignments. During the 10-week trial, iCBT and MAC participants logged into the web-based system six times to complete self-report symptom scales, and a nonclinician technician contacted participants weekly to provide encouragement and support. The primary outcome was the Hamilton Rating Scale for Depression (HRSD), and the secondary outcomes were the Patient Health Questionnaire-9 and Kessler-10. RESULTS: Intent-to-treat analyses revealed significantly greater reductions in depressive symptoms in iCBT compared with MAC participants, using both the self-report measures and the clinician-rated HRSD (d = -0.80). Importantly, iCBT participants also showed significantly higher rates of clinical response and remission. Exploratory analyses did not support illness severity as a moderator of treatment outcome. CONCLUSIONS: The Sadness Program led to significant reductions in depression and distress symptoms. With its potential to be delivered in a scalable, cost-efficient manner, iCBT is a promising strategy to enhance access to effective care.
RCT Entities:
BACKGROUND: Prior research has shown that the Sadness Program, a technician-assisted Internet-based cognitive behavioral therapy (iCBT) intervention developed in Australia, is effective for treating major depressive disorder (MDD). The current study aimed to expand this work by adapting the protocol for an American population and testing the Sadness Program with an attention control group. METHODS: In this parallel-group, randomized controlled trial, adult MDDparticipants (18-45 years) were randomized to a 10-week period of iCBT (n = 37) or monitored attention control (MAC; n = 40). Participants in the iCBT group completed six online therapy lessons, which included access to content summaries and homework assignments. During the 10-week trial, iCBT and MACparticipants logged into the web-based system six times to complete self-report symptom scales, and a nonclinician technician contacted participants weekly to provide encouragement and support. The primary outcome was the Hamilton Rating Scale for Depression (HRSD), and the secondary outcomes were the Patient Health Questionnaire-9 and Kessler-10. RESULTS: Intent-to-treat analyses revealed significantly greater reductions in depressive symptoms in iCBT compared with MACparticipants, using both the self-report measures and the clinician-rated HRSD (d = -0.80). Importantly, iCBTparticipants also showed significantly higher rates of clinical response and remission. Exploratory analyses did not support illness severity as a moderator of treatment outcome. CONCLUSIONS: The Sadness Program led to significant reductions in depression and distress symptoms. With its potential to be delivered in a scalable, cost-efficient manner, iCBT is a promising strategy to enhance access to effective care.
Authors: H D Hadjistavropoulos; N E Pugh; M M Nugent; H Hesser; G Andersson; M Ivanov; C G Butz; G Marchildon; G J G Asmundson; B Klein; D W Austin Journal: J Anxiety Disord Date: 2014-10-08
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Nicolaas P A Zuithoff; Yvonne Vergouwe; Michael King; Irwin Nazareth; Manja J van Wezep; Karel G M Moons; Mirjam I Geerlings Journal: BMC Fam Pract Date: 2010-12-13 Impact factor: 2.497
Authors: Björn Meyer; Thomas Berger; Franz Caspar; Christopher G Beevers; Gerhard Andersson; Mario Weiss Journal: J Med Internet Res Date: 2009-05-11 Impact factor: 5.428
Authors: Randy P Auerbach; Philippe Mortier; Ronny Bruffaerts; Jordi Alonso; Corina Benjet; Pim Cuijpers; Koen Demyttenaere; David D Ebert; Jennifer Greif Green; Penelope Hasking; Elaine Murray; Matthew K Nock; Stephanie Pinder-Amaker; Nancy A Sampson; Dan J Stein; Gemma Vilagut; Alan M Zaslavsky; Ronald C Kessler Journal: J Abnorm Psychol Date: 2018-09-13
Authors: Christian A Webb; Elizabeth A Olson; William D S Killgore; Diego A Pizzagalli; Scott L Rauch; Isabelle M Rosso Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-08-26
Authors: Calista Leung; Julia Pei; Kristen Hudec; Farhud Shams; Richard Munthali; Daniel Vigo Journal: J Med Internet Res Date: 2022-06-15 Impact factor: 7.076
Authors: Robert H Remien; Michael J Stirratt; Nadia Nguyen; Reuben N Robbins; Andrea N Pala; Claude A Mellins Journal: AIDS Date: 2019-07-15 Impact factor: 4.177
Authors: Peter Fromberger; Sonja Schröder; Louisa Bauer; Bruno Siegel; Safiye Tozdan; Peer Briken; Claudia Buntrock; Sonja Etzler; Martin Rettenberger; Andreas Leha; Jürgen L Müller Journal: Front Psychiatry Date: 2021-01-08 Impact factor: 4.157
Authors: Parya Saberi; Caravella McCuistian; Emily Agnew; Angie R Wootton; Dominique A Legnitto Packard; Carol Dawson-Rose; Mallory O Johnson; Valerie A Gruber; Torsten B Neilands Journal: Telemed Rep Date: 2021-01-07
Authors: Eirini Karyotaki; Orestis Efthimiou; Clara Miguel; Frederic Maas Genannt Bermpohl; Toshi A Furukawa; Pim Cuijpers; Heleen Riper; Vikram Patel; Adriana Mira; Alan W Gemmil; Albert S Yeung; Alfred Lange; Alishia D Williams; Andrew Mackinnon; Anna Geraedts; Annemieke van Straten; Björn Meyer; Cecilia Björkelund; Christine Knaevelsrud; Christopher G Beevers; Cristina Botella; Daniel R Strunk; David C Mohr; David D Ebert; David Kessler; Derek Richards; Elizabeth Littlewood; Erik Forsell; Fan Feng; Fang Wang; Gerhard Andersson; Heather Hadjistavropoulos; Heleen Christensen; Iony D Ezawa; Isabella Choi; Isabelle M Rosso; Jan Philipp Klein; Jason Shumake; Javier Garcia-Campayo; Jeannette Milgrom; Jessica Smith; Jesus Montero-Marin; Jill M Newby; Juana Bretón-López; Justine Schneider; Kristofer Vernmark; Lara Bücker; Lisa B Sheeber; Lisanne Warmerdam; Louise Farrer; Manuel Heinrich; Marcus J H Huibers; Marie Kivi; Martin Kraepelien; Nicholas R Forand; Nicky Pugh; Nils Lindefors; Ove Lintvedt; Pavle Zagorscak; Per Carlbring; Rachel Phillips; Robert Johansson; Ronald C Kessler; Sally Brabyn; Sarah Perini; Scott L Rauch; Simon Gilbody; Steffen Moritz; Thomas Berger; Victor Pop; Viktor Kaldo; Viola Spek; Yvonne Forsell Journal: JAMA Psychiatry Date: 2021-04-01 Impact factor: 21.596